ALTTO | ESMO Open

ALTTO | ESMO Open

OVERVIEW Dual anti-human epidermal growth factor receptor 2 (HER2) blockade has improved the outcomes of patients with early and metastatic HER2-positive breast cancer. The final 10-year analysis of the ALTTO trial is presented here. study details The Adjuvant...
APHINITY | Journal of Clinical Oncology

APHINITY | Journal of Clinical Oncology

OVERVIEW The human epidermal growth factor receptor 2 (HER2) is the second most important target for systemic breast cancer (BC) therapy after the estrogen receptor. HER2 overexpression is found in 15%-20% of patients with BC. Today, HER2-directed therapies are...
ALTTO | ESMO Open

Cardiac Safety in the APHINITY trial

OVERVIEW ESMO Open has published an article co-authored by a member of our Biostatistics team. Results of the exploratory analysis conclude that after >6 years of median follow-up, pertuzumab and trastuzumab did not increase cardiotoxicity risk compared to...
Overall survival in the OlympiA trial

Overall survival in the OlympiA trial

OVERVIEW OlympiA demonstrates statistically significant improvement in overall survival with adjuvant olaparib compared with placebo TITLE OF PUBLICATION Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants...